Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy - PubMed (original) (raw)
. 2011 May 15;17(10):3248-58.
doi: 10.1158/1078-0432.CCR-10-0890. Epub 2011 Feb 2.
Affiliations
- PMID: 21288924
- DOI: 10.1158/1078-0432.CCR-10-0890
Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy
Yaozhu Pan et al. Clin Cancer Res. 2011.
Abstract
Purpose: Although autophagy occurs in most tumor cells following DNA damage, it is still a mystery how this DNA-damaging event turns on the autophagy machinery in multiple myeloma (MM) and how the functional status of autophagy impacts on its susceptibility to death in response to DNA-damaging chemotherapy.
Experimental design: We investigate the effects of DNA damage on autophagy in MM cells and elucidate its underlying molecular mechanism. Then, we examined the impacts of pharmacologic or genetic inhibition of autophagy on DNA damage-induced apoptosis. Furthermore, the antimyeloma activity of autophagy inhibitor in combination with DNA-damaging agents was evaluated in MM xenograft models.
Results: We showed that DNA-damaging drugs, doxorubicin and melphalan, induce caspase-dependent apoptosis and concurrently trigger Beclin 1-regulated autophagy in human MM cell lines H929 and RPMI 8226. Mechanistically, association of autophagy execution proteins Beclin 1 with class III phosphoinositide 3-kinase, which is inhibited by Bcl-2 recruitment, contributes directly to the autophagic process. Importantly, targeting suppression of autophagy by minimally toxic concentrations of pharmacologic inhibitors (hydroxychloroquine and 3-methyladenine) or short hairpin RNAs against autophagy genes, Beclin 1 and Atg5, dramatically augments proapoptotic activity of DNA-damaging chemotherapy both in vitro using MM cell lines or purified patient MM cells and in vivo in a human plasmacytoma xenograft mouse model.
Conclusion: These data can help unravel the underlying molecular mechanism of autophagy in DNA-damaged MM cells and also provide a rationale for clinical evaluation of autophagy inhibitors in combination with DNA-damaging chemotherapy in MM.
©2011 AACR.
Similar articles
- Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA, Sanchez E, Steinberg J, Shalitin D, Li ZW, Chen H, Berenson JR. Campbell RA, et al. Eur J Haematol. 2010 Mar;84(3):201-11. doi: 10.1111/j.1600-0609.2009.01384.x. Epub 2009 Nov 18. Eur J Haematol. 2010. PMID: 19929977 - The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
Sanchez E, Shen J, Steinberg J, Li M, Wang C, Bonavida B, Chen H, Li ZW, Berenson JR. Sanchez E, et al. Leuk Res. 2011 Mar;35(3):373-9. doi: 10.1016/j.leukres.2010.06.026. Epub 2010 Jul 21. Leuk Res. 2011. PMID: 20650529 - The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.
Trudel S, Stewart AK, Li Z, Shu Y, Liang SB, Trieu Y, Reece D, Paterson J, Wang D, Wen XY. Trudel S, et al. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):621-9. doi: 10.1158/1078-0432.CCR-06-1526. Clin Cancer Res. 2007. PMID: 17255285 - Synopsis of a roundtable on validating novel therapeutics for multiple myeloma.
Dalton W, Anderson KC. Dalton W, et al. Clin Cancer Res. 2006 Nov 15;12(22):6603-10. doi: 10.1158/1078-0432.CCR-06-1489. Clin Cancer Res. 2006. PMID: 17121878 Review. - Autophagy and Myeloma.
Zheng Z, Wang L, Cheng S, Wang Y, Zhao W. Zheng Z, et al. Adv Exp Med Biol. 2020;1207:625-631. doi: 10.1007/978-981-15-4272-5_45. Adv Exp Med Biol. 2020. PMID: 32671780 Review.
Cited by
- DangER: protein ovERload. Targeting protein degradation to treat myeloma.
Aronson LI, Davies FE. Aronson LI, et al. Haematologica. 2012 Aug;97(8):1119-30. doi: 10.3324/haematol.2012.064923. Epub 2012 May 11. Haematologica. 2012. PMID: 22580998 Free PMC article. Review. - Clioquinol induces pro-death autophagy in leukemia and myeloma cells by disrupting the mTOR signaling pathway.
Cao B, Li J, Zhou X, Juan J, Han K, Zhang Z, Kong Y, Wang J, Mao X. Cao B, et al. Sci Rep. 2014 Jul 18;4:5749. doi: 10.1038/srep05749. Sci Rep. 2014. PMID: 25034786 Free PMC article. - Transcription factor EB is involved in autophagy-mediated chemoresistance to doxorubicin in human cancer cells.
Fang LM, Li B, Guan JJ, Xu HD, Shen GH, Gao QG, Qin ZH. Fang LM, et al. Acta Pharmacol Sin. 2017 Sep;38(9):1305-1316. doi: 10.1038/aps.2017.25. Epub 2017 Jun 12. Acta Pharmacol Sin. 2017. PMID: 28603284 Free PMC article. - Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
Cea M, Cagnetta A, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Roccaro A, Sacco A, Calimeri T, Cottini F, Jakubikova J, Kong SY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC. Cea M, et al. Blood. 2012 Oct 25;120(17):3519-29. doi: 10.1182/blood-2012-03-416776. Epub 2012 Sep 5. Blood. 2012. PMID: 22955917 Free PMC article. - Chemotherapy's effects on autophagy in the treatment of Hodgkin's lymphoma: a scoping review.
Wahyudianingsih R, Sanjaya A, Jonathan T, Pranggono EH, Achmad D, Hernowo BS. Wahyudianingsih R, et al. Discov Oncol. 2024 Jul 8;15(1):269. doi: 10.1007/s12672-024-01142-6. Discov Oncol. 2024. PMID: 38976168 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical